Editorial
Tumor mutational burden as predictive factor of response to immunotherapy
Abstract
In May 2018, Hellmann et al. published in Cancer Cell journal a retrospective study analyzing the predictive value of tumor mutational burden (TMB) in 75 non-small cell lung cancer (NSCLC) patients treated with the combination of the anti PD-1 inhibitor nivolumab and the anti CTLA-4 antibody ipilimumab in the Check-Mate 012 study.
